RARE Nov 2024 45.000 put
- GlobeNewswire
Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual Meeting
NOVATO, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it will present seven abstracts related to its ongoing late-stage program evaluating setrusumab (UX143) and osteogenesis imperfecta (OI), including a late-breaker oral presentation of the 14-month data from the Phase 2/3 Orbit study, at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting. The meeting is being held September 27-30, 2024, in Toronto, Cana
- GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NOVATO, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 62,555 restricted stock units of the company’s common stock to 16 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Empl
- Insider Monkey
Ultragenyx Pharmaceutical Inc. (RARE): Among the Best Mid-Cap Healthcare Stocks To Buy Now
We recently compiled a list of the 10 Best Mid-Cap Healthcare Stocks To Buy Now. In this article, we are going to take a look at where Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) stands against the other mid-cap healthcare stocks. Global Healthcare Market: Growth Projections, Challenges, and Tech-Driven Innovations According to projections by ReportLinker, the market for healthcare […]
